Business Context and Reporting Period
Company: Inmune Bio, Inc. (INMB)
Filing Type: Form 10-Q (Unaudited)
Period: Three months ended March 31, 2025
Business Overview: Inmune Bio is a clinical-stage biotechnology company focused on developing therapies for diseases involving innate immune dysfunction. Key product platforms include DN-TNF (XPro) for Alzheimer's and treatment-resistant depression, CORDStrom for recessive dystrophic epidermolysis bullosa (RDEB), and INKmune for oncology.
Key Financial Metrics
| Metric (in thousands) | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $50 | $14 |
| Net Loss | $(9,739) | $(11,025) |
| Loss Per Share (Basic/Diluted) | $(0.43) | $(0.61) |
| Operating Expenses | $9,955 | $11,031 |
| Research & Development (R&D) | $7,639 | $8,693 |
| General & Administrative (G&A) | $2,316 | $2,338 |
| Cash and Cash Equivalents (End of Period) | $19,337 | $26,002 |
| Net Cash Used in Operating Activities | $(6,824) | $(7,476) |
| Net Cash Provided by Financing Activities | $5,274 | $(2,500) |
| Total Assets | $37,801 | $39,562 |
| Total Liabilities | $8,128 | $7,465 |
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by $1.3 million (11.7%) compared to Q1 2024, driven primarily by a $1.1 million reduction in operating expenses.
- R&D Expenses: R&D expenses declined by $1.1 million, largely due to $1.5 million in reduced costs for the Alzheimer's clinical program as the Phase 2 trial neared completion. This was partially offset by higher employee compensation costs.
- Debt Status: The Company fully repaid its $15 million Term Loan in December 2024. Consequently, interest expense dropped to $0 in Q1 2025 from $357,000 in Q1 2024.
- Financing Activity: The Company raised approximately $5.3 million in net proceeds from the sale of 649,860 shares of common stock under its At-The-Market (ATM) program. In contrast, Q1 2024 saw $2.5 million used for debt repayment.
- Revenue: Revenue increased to $50,000 from $14,000, derived from the sale of mesenchymal stem cells (MSCs) to third parties.
Outlook, Risks, and Management Commentary
Going Concern Warning
Management has raised substantial doubt about the Company's ability to continue as a going concern. With cash and cash equivalents of $19.3 million, the Company projects insufficient liquidity to sustain operations for one year following the issuance of these financial statements. Management is evaluating financing strategies including equity sales, debt financing, government grants, and strategic collaborations.
Product Pipeline Updates
- XPro (Alzheimer's): Phase 2 trial enrollment (208 patients) was completed in late 2024. Data is expected in June 2025. The Company plans an end-of-phase II meeting with the FDA to finalize Phase 3 plans.
- CORDStrom (RDEB): A pivotal blinded randomized cross-over trial is complete. The Company received Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) from the FDA. A Biologics License Application (BLA) is anticipated in the first half of 2026.
- INKmune (Oncology): Phase I/II trial in metastatic castrate-resistant prostate cancer is ongoing, with top-line data expected in the second half of 2025.
- Vendor Dispute: An ongoing dispute exists with a vendor regarding approximately $1.6 million in invoices. The Company has recorded only $0.2 million as an obligation, believing the remaining $1.4 million was invoiced erroneously.
- Regulatory and Development Risk: No products are currently approved for sale. Success depends on clinical trial outcomes and regulatory approvals, which are uncertain.
- Foreign Currency: Operations in the UK and Australia expose the Company to exchange rate fluctuations, though no hedging strategy is currently in place.
- Liquidity Runway: Verify the timeline for securing additional capital given the explicit "substantial doubt" regarding going concern status.
- Vendor Dispute Resolution: Monitor the status of the $1.4 million disputed vendor invoice to assess potential future liability or cash outflow.
- ATM Program Capacity: Confirm remaining capacity under the $75 million ATM agreement (approx. $69.4 million remaining as of March 31, 2025) and recent sales activity post-quarter.
- Clinical Data Readouts: Track the June 2025 data release for the XPro Alzheimer's Phase 2 trial and the subsequent FDA meeting.
- Grant Funding: Verify the status of the $2.0 million NIH grant for the XPro treatment-resistant depression study, as proceeds have not yet been received.